52-Week Range $623.78 $1,249.45 Dividend Yield 0.60% P/E Ratio 40.83 Price Target $1,283.64 Between these, Novo Nordisk may have the more recognizable brands in the GLP-1 space, as it is the maker of both Ozempic and Wegovy
Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum
Together, they provide a comprehensive solution to enhance weight loss, increase vitality, and help you feel your best throughout your journey
However, another drug prides itself on its ability to cause weight loss
Patients pursuing measurable, validated visceral fat reduction typically find that the cost-per-result calculation favors Tesamorelin even at a higher monthly price, because the clinical effect is more reliable
Communicate with your care team If you are struggling to eat enough protein due to nausea or appetite suppression, tell your clinician